OPEN ACCESS Freely available online

Journal of Down Syndrome & Chromosome Abnormalities

Perspective

Types of Screening Tests for Fragile X Syndrome

Kristel Deyn*

Department of Medical Genetics, University of Antwerp, Antwerp, Belgium

DESCRIPTION

Fragile X syndrome is a genetic disorder that affects intellectual and developmental abilities, predominantly in males. As the most common inherited cause of intellectual disability, it is crucial to identify individuals with Fragile X syndrome as early as possible. Screening tests play a vital role in identifying those at risk, enabling timely interventions and support.

Causes

Fragile X syndrome is caused by changes in the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene located on the X chromosome. Individuals with Fragile X syndrome have a repeating sequence of Deoxyribonucleic Acid (DNA) within the gene that leads to the loss of a crucial protein necessary for normal brain development. This loss of protein synthesis results in a range of cognitive, behavioral, and physical characteristics associated with the syndrome.

Early identification of Fragile X syndrome through screening tests offers several advantages. Firstly, it allows for early intervention strategies to be implemented, focusing on improving cognitive, language, and social skills development. Secondly, it provides families with information about their child's condition, enabling them to seek appropriate support and resources. Lastly, identifying Fragile X carriers within families can assist in family planning decisions and genetic counseling.

Screening tests

There are two main types of screening tests used to identify Fragile X syndrome: carrier screening and diagnostic testing.

Carrier screening is performed on individuals who do not display symptoms of the syndrome but may carry the Fragile X gene mutation. This test is particularly important for women of childbearing age as they can pass the mutation on to their children. Carrier screening typically involves a blood test or a buccal swab to collect a DNA sample. The sample is then analyzed to detect changes in the FMR1 gene. If the gene mutation is identified, further testing can be recommended for other family members.

Diagnostic testing, on the other hand, is conducted on individuals showing symptoms associated with Fragile X syndrome, including developmental delays, intellectual disability and certain physical features. Diagnostic testing involves more comprehensive analysis, including DNA sequencing and examining the number of repetitions of the Cytosine-Guanine-Guanine (CGG) trinucleotide in the FMR1 gene.

Early detection of Fragile X syndrome through screening tests allows for early intervention, which can greatly improve the developmental outcomes for affected individuals. Early educational and therapeutic interventions, such as speech and occupational therapy, can help mitigate the impact of cognitive and behavioral challenges associated with the syndrome. Additionally, genetic counseling and support services can assist families in navigating the complexities of Fragile X syndrome and accessing appropriate resources.

Advancements in genetics have paved the way for improved screening techniques and the development of targeted treatments for Fragile X syndrome. Scientists are exploring potential pharmacological interventions aimed at restoring normal protein production and addressing specific symptoms associated with the syndrome.

CONCLUSION

Screening tests for Fragile X syndrome are essential in identifying individuals at risk and providing them with the necessary support and interventions. Early detection allows for timely interventions, improving developmental outcomes and providing vital resources for affected individuals and their families. The studies continues to advance, further refinements in screening methods and therapeutic approaches, ultimately enhancing the quality of life for individuals with Fragile X syndrome. By raising awareness, promoting early screening, and fostering inclusive support systems, can move closer to a future where individuals with Fragile X syndrome can thrive and reach their full potential.

Correspondence to: Dr. Kristel Deyn, Department of Medical Genetics, University of Antwerp, Antwerp, Belgium, Email: kristel@deyn.be

Received: 29-May-2023, Manuscript No. JDSCA-23-24449; **Editor assigned:** 31-May-2023, Pre QC No. JDSCA-23-24449 (PQ); **Reviewed:** 14-Jun-2023, QC No. JDSCA-23-24449; **Revised:** 21-Jun-2023, Manuscript No. JDSCA-23-24449 (R); **Published:** 28-Jun-2023, DOI: 10.35248/2472-1115.23.09.231

Citation: Deyn K (2023) Types of Screening Tests for Fragile X Syndrome. J Down Syndr Chr Abnorm. 09:231